Cargando…
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with m...
Autores principales: | Kaptchuk, Ted J., Friedlander, Elizabeth, Kelley, John M., Sanchez, M. Norma, Kokkotou, Efi, Singer, Joyce P., Kowalczykowski, Magda, Miller, Franklin G., Kirsch, Irving, Lembo, Anthony J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008733/ https://www.ncbi.nlm.nih.gov/pubmed/21203519 http://dx.doi.org/10.1371/journal.pone.0015591 |
Ejemplares similares
-
Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome
por: Hall, Kathryn T., et al.
Publicado: (2012) -
Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial
por: Ballou, Sarah, et al.
Publicado: (2017) -
Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients
por: Hall, Kathryn T, et al.
Publicado: (2015) -
Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome
por: Wang, Rui-Sheng, et al.
Publicado: (2022) -
Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome
por: Vollert, Jan, et al.
Publicado: (2022)